We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+21.97%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.76B
AUM Growth
+$163M
Cap. Flow
-$58.5M
Cap. Flow %
-2.12%
Top 10 Hldgs %
29.44%
Holding
155
New
9
Increased
52
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$21.9M
2
EHC icon
Encompass Health
EHC
+$17.3M
3
ALLK
Allakos
ALLK
+$16.6M
4
ELAN icon
Elanco Animal Health
ELAN
+$13.2M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$9.27M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$26.1M
2
GILD icon
Gilead Sciences
GILD
+$25.9M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$24.1M
4
ACHC icon
Acadia Healthcare
ACHC
+$22.1M
5
NUVA
NuVasive, Inc.
NUVA
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 89.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
101
DELISTED
Cymabay Therapeutics
CBAY
$6.8M 0.25%
613,604
+33,604
+6% +$417K
DERM
102
DELISTED
Dermira, Inc.
DERM
$6.54M 0.24%
600,000
– –
CO
103
DELISTED
Global Cord Blood Corporation
CO
$6.47M 0.23%
925,000
+45,000
+5% +$338K
RYTM icon
104
Rhythm Pharmaceuticals
RYTM
$7.96B
$6.27M 0.23%
215,000
– –
SYRE icon
105
Spyre Therapeutics
SYRE
$9.25B
$6.22M 0.23%
26,000
– –
NVAX icon
106
Novavax
NVAX
$1.31B
$6.11M 0.22%
162,500
– –
IFRX icon
107
InflaRx
IFRX
$271M
$6.09M 0.22%
+177,500
New +$5.73M
ACET icon
108
Adicet Bio
ACET
$74.7M
$6.06M 0.22%
3,571
+1,116
+45% +$1.46M
CLSD
109
DELISTED
Clearside Biomedical
CLSD
$6M 0.22%
65,000
– –
MGNX icon
110
MacroGenics
MGNX
$257M
$5.9M 0.21%
275,000
– –
GBT
111
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.7M 0.21%
150,000
– –
LJPC
112
DELISTED
La Jolla Pharmaceutical Company
LJPC
$5.67M 0.21%
281,800
+59,500
+27% +$1.56M
SPRO icon
113
Spero Therapeutics
SPRO
$73M
$5.52M 0.2%
525,000
– –
ADVM
114
DELISTED
Adverum Biotechnologies
ADVM
$5.45M 0.2%
90,000
– –
BCRX icon
115
BioCryst Pharmaceuticals
BCRX
$2.4B
$5.34M 0.19%
700,000
+450,000
+180% +$3.02M
CRVS icon
116
Corvus Pharmaceuticals
CRVS
$1.17B
$4.93M 0.18%
575,000
– –
NBRV
117
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.86M 0.18%
7,200
+4,640
+181% +$3.29M
CORV
118
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$4.82M 0.17%
1,200,000
– –
SLDB icon
119
Solid Biosciences
SLDB
$900M
$4.48M 0.16%
6,333
– –
PRTK
120
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.37M 0.16%
450,000
– –
CGEN icon
121
Compugen
CGEN
$228M
$4.15M 0.15%
1,078,165
– –
ITCI
122
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.07M 0.15%
187,500
– –
CMTA
123
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$3.85M 0.14%
345,000
– –
VKTX icon
124
Viking Therapeutics
VKTX
$4B
$3.48M 0.13%
+200,000
New +$2.38M
AGN
125
DELISTED
Allergan plc
AGN
$3.37M 0.12%
17,665
– –
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Rock Springs Capital Management held 155 positions worth $2.76B, up 6.3% from $2.6B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management's Q3 2018 filing shows 9 new, 52 increased, 20 reduced and 11 closed positions. Its largest new stake was Allakos: 405,000 shares worth $18.2M. The largest sale was AbbVie, an estimated $26.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier.

  • Rock Springs Capital Management's largest Q3 2018 buy was Allakos: 405,000 shares worth $18.2M.
  • Rock Springs Capital Management added most to Boston Scientific in Q3 2018, an estimated $21.9M increase.
  • Rock Springs Capital Management's biggest Q3 2018 reduction was AbbVie, cutting an estimated $26.1M.
  • Rock Springs Capital Management fully exited Gilead Sciences in Q3 2018, selling an estimated $25.9M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.76B portfolio in Q3 2018.
  • Rock Springs Capital Management opened 9 new positions and closed 11 in Q3 2018.
  • Rock Springs Capital Management's portfolio value rose 6.3% quarter-over-quarter to $2.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.